Ascletis Announces Strategic Decisions On FXR Agonist ASC42 menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
HANGZHOU, China and SHAOXING, China, April 3, 2024 /PRNewswire/ Ascletis Pharma Inc. announces today the strategic decisions on farnesoid X receptor agonist ASC42.
After thorough analysis of.
Ascletis Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
HANGZHOU and SHAOXING, China, Jan. 24, 2024 /PRNewswire/ Ascletis Pharma Inc. today announces dosing of the first patient in Phase III clinical trial of ASC40 for treatment of moderate to.